A Look At Keymed Biosciences (SEHK:2162) Valuation After Annual Results And Commercialization Progress

Simply Wall St.03-29

AdvertisementWhy Keymed Biosciences just drew fresh attention Keymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623359243?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623359243","market":"nz","top_or_hot":-1,"title":"A Look At Keymed Biosciences (SEHK:2162) Valuation After Annual Results And Commercialization Progress","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Keymed Biosciences just drew fresh attention Keymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Keymed Biosciences (SEHK:2162) Valuation After Annual Results And Commercialization Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Keymed Biosciences (SEHK:2162) Valuation After Annual Results And Commercialization Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-29 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Keymed Biosciences just drew fresh attention Keymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual","article_id":"2623359243","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/a-look-at-keymed-biosciences-sehk2162-valuation-after-annual","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623359243","pubTimestamp":1774782626,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Keymed Biosciences just drew fresh attention\nKeymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss in absolute terms, and a slightly smaller loss per share from continuing operations.\nSee our latest analysis for Keymed Biosciences.\nThe latest earnings release and wider shift toward commercialization appear to be feeding into stronger momentum, with a 1-day share price return of 5.03% and a 1-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","02162":"康诺亚-B","BK1161":"生物科技","BK1587":"次新股","PRGS":"Progress Software Corporation","BK4097":"系统软件","BK1574":"生物医药B类股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"年度业绩和商业化进展后看康康生物（SEHK：2162）估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"DCF":1,"02162":0.9},"content_text":"AdvertisementWhy Keymed Biosciences just drew fresh attention Keymed Biosciences (SEHK:2162) has come into focus after releasing its 2025 annual results, with higher reported sales, a wider net loss in absolute terms, and a slightly smaller loss per share from continuing operations. See our latest analysis for Keymed Biosciences. The latest earnings release and wider shift toward commercialization appear to be feeding into stronger momentum, with a 1-day share price return of 5.03% and a 1-year total shareholder return of 34.56%. If Keymed’s move has caught your eye, it can be useful to compare it with other healthcare names that are gaining attention through AI in medicine by scanning 124 healthcare AI stocks With the shares up strongly over the past year, a reported intrinsic discount of about 53% and a wide loss of CN¥522.64 million, you now face a key question: is this a genuine opportunity or is the market already pricing in future growth? Preferred Price-to-Sales of 22x: Is it justified? Keymed Biosciences trades on a P/S of 22x, which sits against a last close of HK$60.55 and suggests the market is placing a rich value on each dollar of current sales compared with peers and the company’s own fair ratio. P/S looks at how much investors are paying for every unit of revenue, which can be useful for early stage or loss making biotech companies where earnings are still negative. A higher P/S often reflects expectations that revenue will scale meaningfully from today’s base, especially when analysts are forecasting strong top line growth. For Keymed Biosciences, that high P/S sits alongside forecast revenue growth of 30% per year and expectations that earnings will improve, including a forecast shift to profitability and a stronger return on equity in future. At the same time, the current 22x P/S is described as expensive relative both to the Hong Kong Biotechs industry average of 12.2x and to the estimated fair P/S of 13.1x. This is a level the market could potentially move toward if sentiment cools on those growth expectations. Compared with peers on 13.1x on average and an industry benchmark of 12.2x, Keymed’s 22x multiple stands out as materially higher. This indicates investors are paying a premium multiple that is well above both sector and model based fair levels. Explore the SWS fair ratio for Keymed Biosciences Result: Price-to-Sales of 22x (OVERVALUED) However, the wide CN¥522.64 million loss and rich 22x P/S, well above industry levels, mean any setback in commercialization or clinical progress could quickly cool sentiment. Find out about the key risks to this Keymed Biosciences narrative. Another view from the SWS DCF model While the 22x P/S ratio looks expensive against peers, the SWS DCF model points the other way, with Keymed Biosciences trading at about a 53% discount to an estimated fair value of HK$129.01 per share. If the cash flow assumptions hold, is the current price more of a discount than a warning? Look into how the SWS DCF model arrives at its fair value. 2162 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Keymed Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 237 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed signals or a clear opportunity: the data is there for you to weigh up and act while sentiment is still forming. To see what is currently exciting investors, review the 3 key rewards Looking for more investment ideas? If Keymed has sharpened your focus, now is the moment to widen the lens and line up a few other ideas before the next move catches you off guard.  Target reliable income streams by scanning a curated set of 471 dividend fortresses that aim to combine higher yields with resilient business profiles. Spot potential mispricings early by checking out screener containing 599 high quality undiscovered gems that pair strong fundamentals with relatively low market attention. Prioritise resilience by focusing on 270 resilient stocks with low risk scores that show steadier risk scores without giving up on long term growth potential.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Keymed Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623359243","isCrawlerRequest":true}